Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
datopotamab deruxtecan + ramucirumab + rilvegostomig
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Datopotamab deruxtecan + ramucirumab + rilvegostomig is an investigational combination therapy for advanced solid tumors, notably non-small cell lung cancer (NSCLC). It comprises three agents with complementary mechanisms: datopotamab deruxtecan, an antibody-drug conjugate targeting TROP2 for direct tumor cell killing; ramucirumab, a monoclonal antibody directed against vascular endothelial growth factor receptor 2 (VEGFR-2) to inhibit tumor angiogenesis; and rilvegostomig, a bispecific monoclonal antibody targeting both TIGIT and PD-1 checkpoints, enhancing anti-tumor immune responses. The combination is being evaluated in late-phase clinical trials for efficacy and safety in various oncologic indications[4][5][2][3][6][7][8].
- Other names
- datopotamab deruxtecan + ramucirumab + rilvegostomig
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)VEGFR2 (Vascular endothelial growth factor receptor 2)TIGIT (T cell immunoreceptor with Ig and ITIM domains)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on datopotamab deruxtecan + ramucirumab + rilvegostomig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on datopotamab deruxtecan + ramucirumab + rilvegostomig.